In this book, distinguished scholars Philip A. Rea, Mark V. Pauly, and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities, the cultures within and between academic and corporate entities, and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies, they consider the fundamental economic underpinnings of investor-driven discovery management, not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim, but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations.
Preface; 1. Discoveries now and then:: shifting incentives and expectations Mark V. Pauly, Philip A. Rea and Lawton R. Burns; 2. Pharma trends:: not what they seem Kyle Myers and Mark V. Pauly; 3. Profit maximizing drug firms:: models and myths Vicki Chen and Mark V. Pauly; Transitional note:: introduction to the case studies; 4. The Statins:: cholesterols penicillins Philip A. Rea; 5. ACE inhibitors:: kidney clamps, snake venoms and peptidomimetics Alec Ren and Philip A. Rea; 6. Angioplasty:: catheters, guidewires and balloons Simon Basseyn, Sourav Bose, Lawton R. Burns and Chris Groskaufmanis; 7. Hepatitis C:: when cures and prices go viral Stephen Goldstein, Peter M. Stokes, Connie Lu and Philip A. Rea; 8. Alzheimers:: Americas new most feared disease Julian Pei, John Q. Trojanowski, Peter M. Stokes, Katherine Clark, Mark V. Pauly and Philip A. Rea; 9. Metformin:: to the brink and back Anderson Y. Tien and Philip A Rea; 10. Medical genomics:: personalized precision Marc S. Williams; 11. Gleevec:: from broken chromosomes to precision cancer therapy Vivek Nimgaonkar and Philip A. Rea; 12. Regeneron:: agility, resilience and balance Lawton R. Burns, Alex Rosen, Steven Nichtberger and Philip A. Rea; 13. Avastin and Lucentis:: both for eyesight in hindsight Osama Ahmed, Mark V. Pauly, Peter M. Stokes and Philip A. Rea; 14. CAR T-cell therapy:: cures for ALL and more? Stephen Goldstein, Amy Le and Philip A. Rea; 15. Organizing discovery:: wild ducks nested in multilevel ecosystems Lawton R. Burns and Philip A. Rea; 16. Can government help with the creatively unexpected? Mark V. Pauly, Lawton R. Burns and Philip A. Rea; Appendix:: three key elements in the discovery process:: historical and philosophical antecedents Mark V. Pauly; Index.
Komentarze (0)
Chwilowo nie możesz polubić tej opinii
Zgłoś komentarz
Czy jesteś pewien, że chcesz zgłosić ten komentarz?
Zgłoszenie wysłane
Twój komentarz został wysłany i będzie widoczny po zatwierdzeniu przez moderatora.